Trial Profile
Preservation of Beta Cell Function in Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Metformin (Primary) ; Pioglitazone (Primary) ; Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 02 Aug 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 02 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Dec 2024.
- 26 Jun 2023 Results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association